GSK Acquires Genelabs to Boost its HCV Pipeline
By Helen Scrutton
Pharma Deals Review: Vol 2008 Issue 101 (Table of Contents)
Published: 29 Oct-2008
DOI: 10.3833/pdr.v2008.i101.120 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
GlaxoSmithKline (GSK) is to acquire Genelabs Technologies for US$57 M in a deal which will boost GSK’s hepatitis C virus (HCV) pipeline...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
Last Issue PDF
RSS